Piper Sandler keeps BioMarin at Overweight, lifts price target
Piper Sandler maintains BioMarin Pharmaceutical at Overweight and raises its price target to $90.00 per share from $88.00.
Ratings actions GMT) BioMarin Pharmaceutical Price Target Raised to $90.00/Share From $88.00 by Piper SandlerRatings actions